Breaking
Vanda Pharmaceuticals Launches NEREUS (Tradipitant) - First New Motion Sickness Drug in 40+ Years Now AvailableTakeda's TAK-881 Meets Primary Endpoint in Phase 2/3 Trial for Primary Immunodeficiency DiseaseFDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Receives Key Diabetes Drug Approval
🌏 NMPA

Cardiovascular

Page 1 • 1 item

Access global pharma market insights on cardiovascular drug development, clinical trials, regulatory approvals, and M&A activity. Stay ahead.

PMDA SAKIGAKE Designation: Accelerating Novel Cardiovascular Drug Approvals
AnalysisCardiovascularApr 22, 2026

PMDA SAKIGAKE Designation: Accelerating Novel Cardiovascular Drug Approvals

Explore the impact of PMDA SAKIGAKE Designation on speeding up the approval process for groundbreaking cardiovascular drugs, including CardioX.

Dr. Priya Sharma